

Special Issue

Immune Modulating Therapeutics for Cancer Immunotherapy & Vaccination

Message from the Guest Editors

We are launching an exciting Special Issue on Immune Modulating Therapeutics for Cancer Immunotherapy & Vaccination. This Special Issue aims to collect original research and review articles on recent developments in the rapidly developing immune engineering field, focusing on immune-modulating therapeutics to empower cancer vaccination and immunotherapy. We are pleased to invite you to contribute to one of the broad topics that synergize the focus of this special issue, e.g., ways to increase cancer immunogenicity (with chemotherapeutics, PDT, radiation, or natural products etc.), novel vaccines to establish long-term anti-cancer immunity, strategies to overcome tumor immune suppression, CAR-T/NK therapeutics, novel antibody therapeutics, immune-modulating drug targets and drug discovery, methods to profile patient biopsy for personalized combinational immunotherapy, and other novel interventions, broadly defined. Thank you, and I look forward to receiving your contributions.

Guest Editors

Dr. Kuo-Ching Mei

Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Dr. Tian Xia

David Geffen School of Medicine, University of California, Los Angeles, CA 94607, USA

Deadline for manuscript submissions

closed (31 August 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/103540

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).